ADC Review / Journal of Antibody-drug Conjugates
ISSN:
2327-0152
Country:
United States
ES-FAC
ES-FAC C
Eurascience Journal Classification System
📄 Articles published in this journal
- Rethinking ADC Design: Lessons from NBE-002 and the Potency of PNU-159682 2026
- TROP-2 and the Promise and Peril of High-Affinity in ADCs 2026
- Antibody-Drug Conjugates in Oncology: Why Potency Is No Longer the Limiting Factor 2026
- Debio 1562M: A First-in-Class CD3-Targeting ADC for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes 2026
- Ifinatamab Deruxtecan Receives FDA Priority Review for Previously Treated Extensive-Stage Small Cell Lung Cancer 2026
- TUB-040: A Next-Generation NaPi2b-Targeted ADC for Ovarian and Lung Cancer 2026
- Conjugation Technologies in ADCs: Innovations, Challenges, Clinical Impact, and Future Directions 2026
- How CDMOs Can Unlock One-step, High-Yield and Homogeneous ADC Manufacturing 2025
- Araris Biotech and Chugai Pharmaceuticals to Develop Next-Generation Tailor-made ADCs 2025
- Emiltatug Ledadotin (XMT-1660) Encouraging Data in mTNBC; Receives Fast Track Designation 2025